Mercado global de doenças da bexiga, por tipo (cistite, incontinência urinária, bexiga hiperativa, cistite intersticial, cancro da bexiga), tipo de tratamento (cirurgia, medicação, não cirúrgico), utilizador final (hospitais, clínicas, centros de cirurgia ambulatória , outros ), distribuição Canal (direto, retalho) - Tendências do setor e previsões até 2029.
Análise e Insights de Mercado de Perturbações da Bexiga
Os distúrbios da bexiga são um grupo de distúrbios que podem afetar as atividades diárias da vida humana. Alguns dos distúrbios mais comuns da bexiga são a cistite, na qual a bexiga é infetada e causa inflamação. Incontinência urinária - perda de controlo da bexiga, cistite intersticial - dor na bexiga e micção frequente e urgente, e bexiga hiperativa - uma condição em que a bexiga comprime a urina. As perturbações da bexiga podem afetar a qualidade de vida e causar outros problemas de saúde. Alterações e problemas de saúde, incluindo fatores do sistema nervoso e estilo de vida, podem causar ou contribuir para a IU em homens e mulheres.
Os distúrbios mais comuns da bexiga são a bexiga hiperativa e a IU. Estes problemas estão associados ao sistema nervoso. Os nervos transmitem mensagens do cérebro para a bexiga, indicando que os músculos se contraem ou relaxam.
Espera-se que o mercado global de distúrbios da bexiga cresça no período previsto de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 11,4% no período previsto de 2022 a 2029 e deverá atingir os EUA 22.342,48 milhões de dólares até 2029.
|
Métrica de Reporte |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (Personalizável 2019-2014) |
|
Unidades quantitativas |
Receita em milhões de dólares americanos |
|
Segmentos abrangidos |
Por tipo (cistite, incontinência urinária, bexiga hiperativa, cistite intersticial, cancro da bexiga), tipo de tratamento (cirurgia, medicação, não cirúrgico), utilizador final (hospitais, clínicas, centros de cirurgia de ambulatório, outros), canal de distribuição (direto , retalho ) |
|
Países abrangidos |
EUA, Canadá, México, Alemanha, Reino Unido, França, Itália, Espanha, Turquia, Rússia, Holanda, Suíça, Bélgica e resto da Europa, China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia , Filipinas , Vietname, Resto da Ásia-Pacífico, Brasil, Argentina, Peru, Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel, Resto do Médio Oriente e África |
|
Atores do mercado abrangidos |
As principais empresas que operam no mercado são a Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (uma subsidiária da KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences entre outros. |
Definição de Mercado do Mercado Global de Perturbações da Bexiga
Os distúrbios relacionados com a bexiga incluem cistite - inflamação da bexiga, geralmente causada por uma infeção, incontinência urinária - perda de controlo da bexiga, bexiga hiperativa - uma condição em que a bexiga expele a urina no momento errado, cistite intersticial - um problema crónico que causa dor e micção frequente e urgente e cancro da bexiga.
Os médicos realizam vários exames para diagnosticar a doença da bexiga, incluindo raios X, análises à urina e um exame da parede da bexiga através de um endoscópio chamado cistoscópio. O tratamento da perturbação depende da causa do problema e inclui medicação, cirurgias (em casos graves) e procedimentos não cirúrgicos.
Os medicamentos anticolinérgicos são a primeira linha de farmacoterapia na síndrome da bexiga hiperativa (BH). A BH é um sintoma clínico caracterizado pela urgência de urinar, que é difícil de adiar. Os medicamentos anticolinérgicos inibem os recetores muscarínicos no músculo detrusor, que reduzem a contratilidade da bexiga. Para reduzir os efeitos secundários, estão a ser desenvolvidos novos medicamentos com seletividade melhorada na bexiga e formulações de libertação prolongada. A maioria dos medicamentos mais recentes são igualmente eficazes na redução dos sintomas da bexiga hiperativa.
Dinâmica do mercado global de distúrbios da bexiga
Motoristas
-
INICIATIVAS ESTRATÉGICAS ADOTADAS PELOS ATORES DO MERCADO
Os distúrbios da bexiga são uma série de problemas da bexiga que podem afetar as atividades físicas diárias. Os distúrbios mais comuns da bexiga são a cistite, a cistite intersticial, a bexiga hiperativa, a incontinência urinária e o cancro da bexiga. A maioria dos problemas de bexiga é causada por uma infeção bacteriana que entra no trato urinário.
Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum rendimentos.
-
POPULAÇÃO GERIÁTRICA CRESCENTE
O envelhecimento é um forte fator de risco que pode estar associado a distúrbios relacionados com a bexiga. O envelhecimento provoca alterações neurológicas, anatómicas e bioquímicas na função da bexiga, podendo resultar no desenvolvimento de BH. A bexiga hiperativa é o problema mais comum na população geriátrica. A população idosa sofre de vários problemas e distúrbios associados à bexiga, sendo, por isso, os principais utilizadores de serviços e soluções de gestão de saúde crónica.
De acordo com o estudo nobre, a taxa de prevalência da bexiga hiperativa é de aproximadamente 16,9 nas mulheres e nos homens, cerca de 16,0%, e a prevalência da BH está a aumentar com a idade. No entanto, as guidelines de tratamento especificam as estratégias preferenciais de terapêutica de primeira, segunda e terceira linha para a BH. Os distúrbios da bexiga estão associados a distúrbios neurológicos, como a demência, e nesta faixa etária, a bexiga hiperativa é muito desafiante para a população idosa. Nas últimas décadas, a população idosa tem crescido drasticamente em todo o mundo.
-
AUMENTO DOS INVESTIMENTOS EM I&D E LANÇAMENTO DE NOVAS TERAPIAS NOS PRÓXIMOS ANOS
Estão disponíveis várias opções de tratamento e terapias inovadoras para a bexiga hiperativa e outros distúrbios da bexiga. Muitas empresas biofarmacêuticas e farmacêuticas estão a investir em diversas terapias não convencionais para as doenças da bexiga, que deverão ser lançadas durante o período previsto.
-
COMBINAÇÃO DE DIFERENTES TERAPIAS-ALVO
As terapias combinadas são muito mais eficazes do que a monoterapia, sem efeitos secundários adicionais. As terapias combinadas são uma alternativa segura e eficaz para indivíduos com condições refratárias da bexiga. Combinar diferentes estratégias de terapia dirigida é a melhor abordagem para aliviar os distúrbios da bexiga nos doentes. Os medicamentos orais e a terapia comportamental devem ser considerados para o tratamento refratário dos doentes. Estão disponíveis várias terapias-alvo avançadas, como a neuromodulação sacral, a injeção intradetrusora de toxina botulínica A e a estimulação percutânea do nervo tibial. Estes são tratamentos avançados e mais eficazes quando comparados com os agentes orais.
Oportunidades
-
SURTO DE NOVOS AVANÇOS TECNOLÓGICOS
As doenças crónicas são consideradas uma das principais causas de morte nos países em desenvolvimento de todo o mundo. Portanto, a importância da gestão dos cuidados de saúde crónicos aumenta entre os profissionais de saúde pública.
O tratamento das doenças da bexiga dá agora grande ênfase à assistência aos doentes com uma série de alternativas de autocuidado e uma variedade de serviços de consulta para educar os doentes sobre o seu estado de doença e seguir em frente. Estas terapias também ajudam os doentes a ultrapassar traumas emocionais e ansiedade, o que pode atuar como um mecanismo de contraproteção.
Os crescentes avanços técnicos permitem às organizações de saúde explorar serviços e soluções inovadores para o tratamento de doenças crónicas da bexiga. Como não têm de estar internados por um longo período, também reduzem os custos e o volume de doentes. Além disso, a redução de visitas e internamentos hospitalares torna este desenvolvimento conveniente para os adultos mais velhos. Considerando os aspetos favoráveis, muitas organizações e empresas estão a desenvolver e a implementar as mais recentes tecnologias na gestão de doenças crónicas para melhorar os resultados dos doentes.
-
PROGRAMAS DE GESTÃO DE DOENÇAS EM CRESCIMENTO
As pessoas com problemas relacionados com a bexiga geralmente precisam de mais serviços médicos, como internamentos hospitalares, consultas médicas e medicamentos prescritos. O aumento do número de pessoas que vivem mais tempo com muitos problemas crónicos e o aumento dos gastos com a saúde têm incentivado melhores planos de saúde.
A gestão da doença é uma estratégia que tenta melhorar os cuidados e, ao mesmo tempo, reduzir as despesas com o tratamento de doentes crónicos. Os programas de gestão de doenças visam melhorar a saúde das pessoas com determinados distúrbios crónicos, tais como distúrbios da bexiga, ao mesmo tempo que reduzem a procura de serviços médicos e as despesas associadas a consequências que podem ser evitadas, tais como internamentos hospitalares e visitas de emergência. Estes programas incluem também informações sobre serviços e soluções de gestão de doenças crónicas. Estão a tornar-se muito populares devido à crescente prevalência de doenças crónicas no mundo inteiro. As organizações governamentais e de saúde organizaram e implementaram estas doenças crónicas com vários programas de gestão de doenças, como o cancro da bexiga, a cistite intersticial e os programas de gestão da bexiga hiperativa. Uma vez que os programas de gestão de doenças podem melhorar significativamente as práticas de autocuidado e reduzir as visitas e os períodos de internamento hospitalar em maior medida, recebem mais atenção entre as pessoas.
Restrições/Desafios
No entanto, a dificuldade em diagnosticar a doença e o custo dos tratamentos e diagnósticos são elevados devido ao procedimento de vários pontos de verificação, juntamente com as tecnologias e modalidades de alta tecnologia para realizar os procedimentos. O custo do procedimento é geralmente elevado devido ao elevado custo dos dispositivos tecnológicos avançados utilizados no tratamento, o que deverá restringir o crescimento do mercado.
Este relatório de mercado sobre distúrbios da bexiga fornece detalhes de novos desenvolvimentos recentes, regulamentos comerciais, análise de importação e exportação, análise de produção, otimização da cadeia de valor, quota de mercado, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, análise estratégica do crescimento do mercado, tamanho do mercado, crescimento do mercado das categorias, nichos de aplicação e dominância, aprovações de produtos, lançamentos de produtos, expansões geográficas, inovações tecnológicas no mercado. Para mais informações sobre o mercado global de doenças da bexiga, contacte a Data Bridge Market Research para obter um resumo analítico. A nossa equipa irá ajudá-lo a tomar uma decisão de mercado informada para alcançar o crescimento do mercado.
Impacto pós-COVID-19 no mercado global de doenças da bexiga
A COVID-19 afetou positivamente o mercado. Os bloqueios e isolamentos durante as pandemias complicam a gestão de doenças e a adesão à medicação. Por este motivo, o uso de vários medicamentos para o tratamento aumentou amplamente na população mundial. Portanto, a pandemia teve um efeito positivo neste mercado
Desenvolvimento recente
- Em junho de 2022, a Valencia Technologies Corporation anunciou o produto de tecnologia de neuromodulação implantável eCoin®, que está a reformular o fornecimento de terapia de longo prazo para o controlo da bexiga, é um implante tibial para incontinência urinária de urgência (IUU). O eCoin® recebeu a aprovação pré-comercialização (PMA) da Food and Drug Administration (FDA) dos EUA em março de 2022, tornando-se o primeiro e único neuroestimulador tibial implantável aprovado pela FDA indicado para o tratamento de incontinência urinária de urgência (IUU ). Este novo produto ajudou a empresa a aumentar o seu portfólio
Âmbito do mercado global de distúrbios da bexiga
O mercado global de doenças da bexiga está segmentado em tipos de tratamento, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar segmentos de crescimento escassos nos setores e fornecerá aos utilizadores uma visão geral e informações valiosas do mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.
Tipo
- Cistite
- Incontinência urinária
- Bexiga hiperativa
- Cistite Intersticial
- Cancro de bexiga
Com base no tipo, o mercado global de doenças da bexiga está segmentado em cistite, incontinência urinária, bexiga hiperativa, cistite intersticial e cancro da bexiga.
Tipo de tratamento
- Cirurgia
- Medicamentos
- Outros
Com base no produto, o mercado global de distúrbios da bexiga está segmentado em cirurgia, medicamentos e outros.
Utilizador final
- Hospital
- Clínicas
- Centros de Cirurgia Ambulatória
- Outros
Com base nos utilizadores finais, o mercado global de doenças da bexiga está segmentado em hospitais, clínicas, centros de cirurgia ambulatória e outros.
Canal de Distribuição
- Direto
- Retalho
Com base no canal de distribuição, o mercado global de distúrbios da bexiga está segmentado em direto e retalho.
Análise/Insights Regionais do Mercado Global de Perturbações da Bexiga
The global bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.
Countries covered in this market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa.
North America dominates the global bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Bladder Disorders Market Share Analysis
The global bladder disorders market competitive landscape provides details about the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the company’s focus on the global bladder disorders market.
Some of the major players operating in the global bladder disorders market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences among others.
Research Methodology
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com grandes tamanhos de amostra. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados, que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem a grelha de posicionamento de fornecedores, análise da linha do tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise da quota de mercado da empresa, padrões de medição, global vs. de participação dos fornecedores. Solicite uma chamada de analista em caso de dúvidas adicionais.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BLADDER DISORDERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 GLOBAL BLADDER DISORDERS MARKET, PIPELINE ANALYSIS
5 GLOBAL BLADDER DISORDER MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS
6 GLOBAL BLADDER DISORDERS MARKET OVERVIEW
6.1 DRIVERS
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT
6.2.2 PRODUCTS RECALLS FROM MARKET
6.3 OPPORTUNITIES
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS
6.4.2 PATENT EXPIRY OF DRUGS
7 GLOBAL BLADDER DISORDERS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVERACTIVE BLADDER
7.3 URINARY INCONTINENCE
7.4 CYSTITIS
7.5 INTERSTITIAL CYSTITIS
7.6 BLADDER CANCER
7.7 OTHERS
8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATION
8.2.1 TOLTERODINE
8.2.2 MIRABEGRON
8.2.3 FESOTERODINE
8.2.4 OXYBUTYNIN
8.2.5 SOLIFENACIN
8.2.6 DARIFENACIN
8.2.7 TROSPIUM
8.2.8 OTHERS
8.3 SURGERY
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY
8.3.2 BLADDER REMOVAL
8.3.3 OTHERS
8.4 OTHERS
9 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT
9.3 RETAIL
10 GLOBAL BLADDER DISORDERS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 OTHERS
11 GLOBAL BLADDER DISORDERS MARKET, BY GEOGRAPHY
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 U.K.
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 TURKEY
11.3.7 RUSSIA
11.3.8 NETHERLANDS
11.3.9 SWITZERLAND
11.3.10 BELGIUM
11.3.11 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 THAILAND
11.4.7 SINGAPORE
11.4.8 INDONESIA
11.4.9 MALAYSIA
11.4.10 VIETNAM
11.4.11 PHILIPPINES
11.4.12 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SAUDI ARABIA
11.6.2 SOUTH AFRICA
11.6.3 UAE
11.6.4 EGYPT
11.6.5 ISRAEL
11.6.6 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL BLADDER DISORDERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC. (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ASTELLAS PHARMA INC. (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 VIATRIS INC. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 AXONICS, INC. (2021)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BLUE WIND MEDICAL (2021)
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 COLOPLAST CORP. (2021)
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 LABORIE (2021)
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDTRONIC (2021)
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 PFIZER INC. (2021)
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 VALENCIA TECHNOLOGIES (2021)
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 SWATI SPENTOSE (2021)
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 UROVANT SCIENCES (2021)
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 ZYDUS GROUP (2021)
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 GLOBAL OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 U.S. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 U.S. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 32 U.S. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 33 U.S. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 U.S. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 35 U.S. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 CANADA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 CANADA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 CANADA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 39 CANADA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 40 CANADA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 CANADA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MEXICO BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MEXICO BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 MEXICO MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 MEXICO SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 MEXICO BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 47 MEXICO BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 EUROPE BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 GERMANY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 GERMANY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 58 GERMANY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 59 GERMANY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 60 GERMANY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 61 U.K. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 U.K. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.K. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.K. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 65 U.K. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 U.K. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 FRANCE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 72 FRANCE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 73 ITALY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 ITALY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 ITALY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 ITALY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 ITALY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 ITALY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 79 SPAIN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 SPAIN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 81 SPAIN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 82 SPAIN. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 SPAIN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 SPAIN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 TURKEY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 TURKEY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 87 TURKEY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 TURKEY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 89 TURKEY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 TURKEY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 95 RUSSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 RUSSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 NETHERLANDS BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 NETHERLANDS BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 99 NETHERLANDS MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 100 NETHERLANDS SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 101 NETHERLANDS BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 102 NETHERLANDS BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 103 SWITZERLAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SWITZERLAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 SWITZERLAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 106 SWITZERLAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 SWITZERLAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 108 SWITZERLAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 BELGIUM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 BELGIUM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 111 BELGIUM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 112 BELGIUM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 113 BELGIUM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 BELGIUM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 115 REST OF EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 117 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 119 ASIA-PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 ASIA-PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 CHINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 CHINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 125 CHINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 126 CHINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 127 CHINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 CHINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 129 JAPAN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 JAPAN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 131 JAPAN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 JAPAN SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 133 JAPAN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 JAPAN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 INDIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 INDIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 137 INDIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 INDIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 139 INDIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 INDIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 AUSTRALIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 AUSTRALIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 143 AUSTRALIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 AUSTRALIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 145 AUSTRALIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 146 AUSTRALIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 147 SOUTH KOREA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 SOUTH KOREA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 149 SOUTH KOREA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 150 SOUTH KOREA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 151 SOUTH KOREA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 SOUTH KOREA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 153 THAILAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 THAILAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 155 THAILAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 156 THAILAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 157 THAILAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 158 THAILAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 159 SINGAPORE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 SINGAPORE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 161 SINGAPORE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 SINGAPORE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 163 SINGAPORE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 SINGAPORE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 INDONESIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 INDONESIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 INDONESIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 168 INDONESIA. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 169 INDONESIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 170 INDONESIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 171 MALAYSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 MALAYSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 173 MALAYSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 174 MALAYSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 175 MALAYSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 MALAYSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 VIETNAM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 VIETNAM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 179 VIETNAM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 180 VIETNAM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 181 VIETNAM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 182 VIETNAM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 183 PHILIPPINES BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 PHILIPPINES BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 185 PHILIPPINES MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 186 PHILIPPINES SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 187 PHILIPPINES BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 188 PHILIPPINES BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 189 REST OF ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 SOUTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 191 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 193 SOUTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 194 SOUTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 195 SOUTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 196 SOUTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 197 BRAZIL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 BRAZIL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 199 BRAZIL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 200 BRAZIL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 201 BRAZIL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 202 BRAZIL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 203 ARGENTINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 ARGENTINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 205 ARGENTINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 206 ARGENTINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 207 ARGENTINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 ARGENTINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 209 REST OF SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 211 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 MIDDLE EAST AND AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 214 MIDDLE EAST AND AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 215 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 216 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 217 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 219 SAUDI ARABIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 220 SAUDI ARABIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 221 SAUDI ARABIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 222 SAUDI ARABIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 223 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 225 SOUTH AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 226 SOUTH AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 227 SOUTH AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 228 SOUTH AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 229 UAE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 UAE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 231 UAE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 232 UAE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 233 UAE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 234 UAE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 235 EGYPT BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 EGYPT BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 237 EGYPT MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 238 EGYPT SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 239 EGYPT BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 240 EGYPT BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 241 ISRAEL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ISRAEL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 243 ISRAEL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 244 ISRAEL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 245 ISRAEL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 246 ISRAEL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 247 REST OF MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 2 GLOBAL BLADDER DISORDERS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BLADDER DISORDERS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE GLOBAL BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLADDER DISORDERS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLADDER DISORDERS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR BLADDER DISORDERS MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BLADDER DISORDER MARKET
FIGURE 16 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2021
FIGURE 17 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021
FIGURE 21 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 22 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 23 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2021
FIGURE 29 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 30 GLOBAL BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 31 GLOBAL BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 33 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021)
FIGURE 34 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2022 & 2029)
FIGURE 35 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021 & 2029)
FIGURE 36 GLOBAL BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 37 NORTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 38 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 39 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 40 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 41 NORTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 42 EUROPE BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 47 ASIA-PACIFIC BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 48 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 49 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 50 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 51 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 52 SOUTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 53 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 54 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 55 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 56 SOUTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 57 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 58 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 59 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 60 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 61 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 62 GLOBAL BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 63 NORTH AMERICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 EUROPE BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 65 ASIA-PACIFIC BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
